ArticleFrontiers in medicine2025
Independent role of two novel abdominal fat indicators in chronic diarrhoea.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Studies have confirmed that obesity is an antecedent of chronic diarrhoea, and new evidence suggests that visceral fat accumulation may play a more critical role than total body fat in intestinal dysfunction and the development of chronic diarrhoea. Traditional body mass index (BMI) does not accurately reflect fat distribution, limiting the depth of relevant research. Body shape index (ABSI) and body rounding index (BRI), as emerging measurements that more accurately assess abdominal and visceral adiposity, have shown superior predictive value to BMI in cardiovascular and metabolic diseases. However, the use of these metrics in the prediction of chronic diarrhoea has not been explored. This study is the first to investigate the relationship between ABSI and BRI and chronic diarrhoea, aiming to provide a new clinical tool for risk assessment of obesity-related diarrhoea. Methods: This study used data from the Bowel Health Questionnaire (BHQ) of the U.S. National Health Examination Survey (NHANES) database (2005-2010), and chronic diarrhoea was defined as "chronic diarrhoea" by the Bristol Stool Scale (BSFS) types 6 andI7(4). Weighted logistic regression and trend analyses were performed to examine the association between ABSI/BRI and chronic diarrhoea. Flexible restricted cubic spline (RCS) models showed dynamic associations. Stratified analyses examined associations between age, gender, race, and clinical characteristics (e.g., cardiovascular disease, diabetes, hypertension). Receiver operating characteristic (ROC) curves assessed the predictive performance of ABSI/BRI for risk of chronic diarrhoea. Results: Multivariate regression models with time-trend analyses indicated a dose-response relationship between higher BRI percentiles and the incidence of chronic diarrhoea. 13% per unit increase in BRI (OR = 1.13, 95% CI = 1.08-1.19, Conclusion: The objective of this study was to investigate the association between two novel abdominal fat indicators (ABSI and BRI) and chronic diarrhoea using nationally representative NHANES data (2005-2010). For the first time, we have identified ABSI and BRI as potentially useful clinical predictors of chronic diarrhoea.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.